The authors assessed the efficacy and safety of rosuvastatin monotherapy, extended-release (ER) niacin monotherapy, or rosuvastatin and ER niacin combined therapy in patients with atherogenic ...

Stockholm, Sweden - Rosuvastatin (ZD4522), which is in late clinical development at AstraZeneca, appears to be more potent than any other available lipid-lowering agent, leading to its being ...

Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as ...